Volume 49, Issue 1 (5-2025)
Research in Medicine 2025, 49(1): 0-0 |
Back to browse issues page
Ethics code: IR.IAU.NEYSHABUR.REC.1403.038
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Edalatian Tavakoli S, Motavalizadehkakhky A, Homayouni Tabrizi M, Mehrzad J, Zhiani R. Evaluation of the Antibacterial Effects of Ambleprenin Loaded on Polydopamine-Linked Mesoporous Silica Nanoparticles (APS-NPs). Research in Medicine 2025; 49 (1)
URL: http://pejouhesh.sbmu.ac.ir/article-1-3423-en.html
URL: http://pejouhesh.sbmu.ac.ir/article-1-3423-en.html
Sedigheh Edalatian Tavakoli 
, Alireza Motavalizadehkakhky , Masoud Homayouni Tabrizi , Jamshid Mehrzad , Rahele Zhiani
, Alireza Motavalizadehkakhky , Masoud Homayouni Tabrizi , Jamshid Mehrzad , Rahele Zhiani
Islamic Azad University , amotavalizadeh@yahoo.com
Abstract: (26 Views)
Background and Aim:The global rise in antibiotic-resistant bacteria has become a critical challenge in healthcare, emphasizing the need for alternative therapeutic strategies. This study aimed to evaluate the antibacterial and anti-biofilm effects of umbelliferone (UMB) loaded into mesoporous silica nanoparticles (MSN) conjugated with polydopamine (PDA)—a novel nanoformulation referred to as APS-NP—investigated for the first time in this context.
Methods:In this experimental study, APS-NPs were synthesized by loading umbelliferone into mesoporous silica nanoparticles, followed by conjugation with polydopamine. Particle size and morphology were characterized using dynamic light scattering (DLS) and field emission scanning electron microscopy (FESEM). The antibacterial activity of APS-NPs was tested against Gram-positive bacteria (Bacillus subtilis and Staphylococcus aureus) and Gram-negative bacteria (Escherichia coli and Pseudomonas aeruginosa) using the Kirby-Bauer agar diffusion method, as well as by determining the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Biofilm inhibition was assessed using disk diffusion and agar diffusion methods. Statistical analysis was conducted using one-way ANOVA with SPSS version 21, with significance set at p<0.05.
Results:The synthesized APS-NPs had an average size of 196.7 ± 0.21 nm and a zeta potential of −41.07 mV, exhibiting a spherical morphology. APS-NPs demonstrated potent antibacterial effects, particularly against Gram-positive strains. The MIC values for Bacillus subtilis and Staphylococcus aureus were 50 µg/mL and 25 µg/mL, respectively. Additionally, APS-NPs effectively inhibited biofilm formation by Bacillus subtilis (25 ± 0.036) at 200 µg/mL and Staphylococcus aureus (5 ± 0.0) at 125 µg/mL (p<0.05), with significant inhibition also observed at 300 µg/mL (p<0.05).
Conclusion:APS-NPs represent a promising nano-based strategy for combating antibiotic-resistant bacterial infections and inhibiting biofilm formation. These findings highlight their potential as an innovative alternative to conventional antimicrobial therapies. However, further preclinical and clinical studies are required to assess their safety, toxicity, and therapeutic efficacy in vivo.
Methods:In this experimental study, APS-NPs were synthesized by loading umbelliferone into mesoporous silica nanoparticles, followed by conjugation with polydopamine. Particle size and morphology were characterized using dynamic light scattering (DLS) and field emission scanning electron microscopy (FESEM). The antibacterial activity of APS-NPs was tested against Gram-positive bacteria (Bacillus subtilis and Staphylococcus aureus) and Gram-negative bacteria (Escherichia coli and Pseudomonas aeruginosa) using the Kirby-Bauer agar diffusion method, as well as by determining the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Biofilm inhibition was assessed using disk diffusion and agar diffusion methods. Statistical analysis was conducted using one-way ANOVA with SPSS version 21, with significance set at p<0.05.
Results:The synthesized APS-NPs had an average size of 196.7 ± 0.21 nm and a zeta potential of −41.07 mV, exhibiting a spherical morphology. APS-NPs demonstrated potent antibacterial effects, particularly against Gram-positive strains. The MIC values for Bacillus subtilis and Staphylococcus aureus were 50 µg/mL and 25 µg/mL, respectively. Additionally, APS-NPs effectively inhibited biofilm formation by Bacillus subtilis (25 ± 0.036) at 200 µg/mL and Staphylococcus aureus (5 ± 0.0) at 125 µg/mL (p<0.05), with significant inhibition also observed at 300 µg/mL (p<0.05).
Conclusion:APS-NPs represent a promising nano-based strategy for combating antibiotic-resistant bacterial infections and inhibiting biofilm formation. These findings highlight their potential as an innovative alternative to conventional antimicrobial therapies. However, further preclinical and clinical studies are required to assess their safety, toxicity, and therapeutic efficacy in vivo.
Keywords: Ambleprenin loaded on polydopamine-linked mesoporous silica nanoparticles (APS-NP), Amblyprenin, Mesoporous Silica Nanoparticles, Polydopamine
Type of Study: Original |
Subject:
Biothecnology
Received: 2024/10/25 | Accepted: 2025/03/11 | Published: 2025/09/14
Received: 2024/10/25 | Accepted: 2025/03/11 | Published: 2025/09/14
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This Journal is licensed under a Creative Commons Attribution 4.0 International License | Research in Medicine
Designed & Developed by : Yektaweb